Series C · Biotech
Sling Therapeutics raises $123m Series C for thyroid eye disease drug
Forbion led the financing for clinical development of linsitinib, an oral candidate being studied for thyroid eye disease.
An oral candidate enters Phase 3
Sling is advancing linsitinib, an oral inhibitor of the IGF-1 receptor, as a potential treatment for thyroid eye disease. The drug is being evaluated in the global Phase 3 ORBIT trial, where the first patients were dosed in September.
Linsitinib is designed as an oral option for a condition whose treatment can impose a burden on patients and clinicians. The candidate remains investigational; Sling says it has received FDA Fast Track designation and has an established safety record from studies involving more than 900 patients across multiple diseases.
Use of funds
Continue clinical advancement of linsitinib for thyroid eye disease
Funding history
Series C · This round$123M